This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Some diseases are caused by mutations in large genes that exceed the packaging limits of existing vectors like adeno-associated virus (AAV). Although the therapy did coax cells to make functional CFTR proteins, patients showed only modest clinical improvements. Vectors also differ in the duration of their expression.
The virus SARS-CoV-2 emerged in Wuhan, home of a premiere research institute that focuses on viruses. An altered virus could have escaped. Evidence that the virus emerged, or escaped, from the wildlife trade is lacking. On April 15, 2021, I posted “ 3 Possible Origins of COVID: Lab Escapee, Evolution, or Mutator Genes?
25, 2021 /PRNewswire/ — Elasmogen Ltd , the pioneering biopharmaceutical company leading the development of VNAR and soloMER biologics, today announces a significant breakthrough in the identification of next-generation protein-based drugs potentially capable of stopping COVID-19 infections. ABERDEEN, Scotland , Jan.
Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. The deal will provide Biogen the rights to use the technology across their portfolio of gene therapy products.
Read *An engineered influenza virus to deliver antigens for lung cancer vaccination. Read Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies. Read Maximizing proteinproduction by keeping cells at optimal secretory stress levels using real-time control approaches. Only about 1.5
Read *An engineered influenza virus to deliver antigens for lung cancer vaccination. Read Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies. Read Maximizing proteinproduction by keeping cells at optimal secretory stress levels using real-time control approaches. Only about 1.5
Ricin is toxic because it inactivates ribosomes, RNA-protein machines that translate each triplet codon of mRNA into its corresponding amino acid, linking them together to form peptides and proteins. This is the step after the initial transcription of DNA into mRNA by RNA Polymerase II, the protein to which alpha amanitin binds.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content